Clinical Trial Update: Sequential Use of AG and mFOLFIRINOX as Neoadjuvant Chemotherapy for Resectable Pancreatic Cancer [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating sequential AG regimen (nab-paclitaxel + gemcitabine) followed by modified FOLFIRINOX as neoadjuvant chemotherapy for resectable pancrea…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• 5-Fluorouracil (5-FU)
• Folinic acid (folinic acid)
• Gemcitabine (Gemcitabine)
• Irinotecan (Irinotecan)
• Nab-paclitaxel (paclitaxel protein-bound)
• OXALIPLATIN (Oxaliplatin)

Snippet

Sponsor: Second Affiliated Hospital, School of Medicine, Zhejiang University | Conditions: Pancreatic Adenocarcinoma Resectable, Neoadjuvant Chemotherapy | Phase 3 | Status: COMPLETED